Regeneron Pharmaceuticals, Inc. (REGN) Q1 2018 Earnings Results

Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.26%

Regeneron's earnings report showed a positive surprise in EPS, which reflects the company's profitability. However, the stock fell by 1.26%, likely due to the absence of revenue guidance and uncertainty about future performance. Investors may be cautious as they await more details on revenue expectations.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$4.70	N/A	+0.42%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, indicating a strong performance. However, they did not provide specific guidance for future revenue.

We are pleased with our EPS performance this quarter.

While we did not provide revenue guidance, we remain focused on our pipeline.

Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.26%

Key numbers

Management commentary

Regeneron Pharmaceuticals, Inc.

More earnings this week

Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.26%

Key numbers

Management commentary